Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aeterna Zentaris (AEZS) shares

Learn how to easily invest in Aeterna Zentaris shares.

Aeterna Zentaris is a biotechnology business based in the US. Aeterna Zentaris stocks (AEZS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.9 – an increase of 5.88% over the previous week. Aeterna Zentaris employs 12 staff and has a trailing 12-month revenue of around $4.2 million.

How to buy shares in Aeterna Zentaris

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AEZS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aeterna Zentaris stock price (NASDAQ:AEZS)

Use our graph to track the performance of AEZS stocks over time.

Aeterna Zentaris shares at a glance

Information last updated 2022-01-25.
Latest market close$0.36
52-week range$0.30 - $3.62
50-day moving average $0.42
200-day moving average $0.69
Wall St. target price$2.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.07

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Aeterna Zentaris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aeterna Zentaris price performance over time

Historical closes compared with the close of $0.36 from 2022-01-25

1 week (2022-01-15) N/A
1 month (2021-12-23) -14.33%
3 months (2021-10-22) N/A
6 months (2021-07-26) -49.30%
1 year (2021-01-26) -46.97%
2 years (2020-01-24) -70.25%
3 years (2019-01-25) 3.63
5 years (2017-01-26) 2.6

Aeterna Zentaris financials

Revenue TTM $4.2 million
Gross profit TTM $1.3 million
Return on assets TTM -7.1%
Return on equity TTM -17.3%
Profit margin -156.35%
Book value $0.49
Market capitalisation $42 million

TTM: trailing 12 months

Aeterna Zentaris share dividends

We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.

Have Aeterna Zentaris's shares ever split?

Aeterna Zentaris's shares were split on a 1:100 basis on 19 November 2015. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.

Aeterna Zentaris share price volatility

Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $0.2971 up to $3.62. A popular way to gauge a stock's volatility is its "beta".

AEZS.US volatility(beta: 2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 2.0044. This would suggest that Aeterna Zentaris's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aeterna Zentaris overview

Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maximilians-University Wuerzburg for the development of an oral prophylactic bacterial vaccine against COVID-19 disease; development, manufacture, and commercialization of targeted immunosuppressive therapeutic proteins for the treatment of neuromyelitis optica spectrum disorder. It also has a license agreement with Consilient Health Ltd.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site